KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to -$5.9 million.

  • Esperion Therapeutics' Change in Inventory fell 3572.25% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.4 million, marking a year-over-year decrease of 80.23%. This contributed to the annual value of $28.9 million for FY2024, which is 510.81% down from last year.
  • Esperion Therapeutics' Change in Inventory amounted to -$5.9 million in Q3 2025, which was down 3572.25% from $15.1 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Change in Inventory peaked at $15.1 million during Q2 2025, and registered a low of -$6.4 million during Q2 2022.
  • Over the past 5 years, Esperion Therapeutics' median Change in Inventory value was $4.8 million (recorded in 2025), while the average stood at $4.9 million.
  • In the last 5 years, Esperion Therapeutics' Change in Inventory tumbled by 27432.14% in 2022 and then soared by 173993.61% in 2023.
  • Esperion Therapeutics' Change in Inventory (Quarter) stood at $422000.0 in 2021, then soared by 1240.28% to $5.7 million in 2022, then skyrocketed by 150.85% to $14.2 million in 2023, then rose by 1.42% to $14.4 million in 2024, then tumbled by 141.19% to -$5.9 million in 2025.
  • Its Change in Inventory stands at -$5.9 million for Q3 2025, versus $15.1 million for Q2 2025 and $4.8 million for Q1 2025.